口服氟达拉滨治疗慢性淋巴细胞白血病/小淋巴细胞瘤患者的疗效观察(英文)  

Efficacy of oral fludarabine in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

作　　者：祝焱[1] 秦群[2] 谢兆霞[1] 

机构地区：[1]中南大学湘雅医院血液科,长沙410008 [2]中南大学湘雅医院药剂科,长沙410008

出　　处：《中南大学学报（医学版）》2013年第3期221-224,共4页Journal of Central South University ：Medical Science

摘　　要：目的:观察口服氟达拉滨治疗慢性淋巴细胞白血病/小淋巴细胞瘤(chronic lymphocytic leukemia/smalllymphocytic lymphoma,CLL/SLL)患者的疗效及耐受性。方法:患者口服氟达拉滨片40 mg/(m2.d),连续5 d,每4周一个疗程。根据美国国立癌症综合网络(National Comprehensive Cancer Network,NCCN)中CLL/SLL治疗指南标准判断疗效。结果:22例患者接受了治疗,每例患者中位疗程为4疗程。完全缓解(complete response,CR)率40.9%(9/22),部分缓解(partial response,PR)率45.5%(10/22),总有效(overall response,OR)率86.4%(19/22)。17例初治患者中CR 7例(41.2%),PR 8例(47.0%)。5例复治患者中2例CR,2例PR。中位随访24个月,患者生存率为81.8%。主要的不良反应为骨髓抑制和感染。7例(31.8%)患者发生I～III级的中性粒细胞减少,3例(13.6%)患者发生感染。非血液学毒性轻微。不良反应均可恢复。结论:口服氟达拉滨对于CLL/SLL患者安全、有效,并且耐受性较好。Objective： To investigate the efficacy and safety of oral fludarabine in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma （CLL/SLL）. Methods： The patients received oral fludarabine 40 mg/（m2-d） for 5 consecutive days, each treatment lasting 4 weeks. The efficacy was assessed with National Comprehensive Cancer Network （NCCN） criteria for response. Results： Twenty-two patients received the treatment, a median of 4 cycles per patient. The rate of complete response （CR）, partial response （PR）, and overall response （OR） was 40.9% （9/22）, 45.5% （10/22）, and 86.4% （19/22）, respectively. Among the 17 previously untreated patients, 7 （41.2%） achieved CR and 8 （47.0%） achieved PR. Two of the 5 pre-treated patients achieved CR and the other 2 achieved PR. During a median observation of 24 months, the overall survival rate was 81.8%. The main adverse reactions were myelosuppression and infection. Grade 1 to 3 granulocytopenia was found in 7 （31.8%） patients, and infection in 3 （13.6%） patients. Non- hematologic toxicity was mild. All the adverse reactions were reversible. Conclusion： The oral fludarabine is effective, safe, and well-tolerated in the patients with CLL/ SLL.

关 键 词：氟达拉滨 慢性淋巴细胞白血病 小淋巴细胞淋巴瘤 

分 类 号：R733.7[医药卫生—肿瘤]